Stronger Life Science Patents (MichBio)

Aurora Consulting
Aurora ConsultingAurora Consulting
Stronger
Life Science Patents
This presentation is for information purposes only and does not
constitute legal advice.
ASHLEY SLOAT, Ph.D. | September 18, 2023
Ashley Sloat, Ph.D.
President & Director of Patent Strategy
an illogical, unpredictable, chaotic mess...
“
– Federal Circuit Chief Judge Paul Michel (retired)
made it difficult for inventors, businesses, and
other patent stakeholders to reliably and
predictably determine what subject matter is
patent eligible
“
– Elizabeth Prelogar, U.S. Solicitor General
innovation cannot thrive in uncertainty
“
– Kathi Vidal, USPTO Director and Under Secretary of Commerce
80%
innovation does not include patentable subject matter
Innovation doesn’t wait.
Let us be clear: investments in the biotech
industry are based entirely on patents. Without
strong patents, we cannot raise money to find
cures for disease.
“
– Hans Bishop, Founder at Altos Labs & former Head of Juno Therapeutics
Stronger Life Science Patents (MichBio)
Overview: Stronger Life Science Patents
•Eligibility and enablement
•State of the law
•Funding sources and regulatory delays
•Practical tips
•Recent legislative movements
There are seven
days in the week
and SOMEDAY isn’t
one of them.
“
Rejection & Invalidation Gates
• Section 101 – patent ineligibility or lack of utility
• Section 102 – lack of novelty
• Section 103 – the claimed invention is obvious and/or
• Section 112 – lack of adequate description
Eligibility.
What subject matters are eligible for patent protection?
Enablement.
The fundamental deal of the patent system.
Eligibility: Patentable Subject Matter
“Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof,
may obtain a patent therefor, subject to the conditions
and requirements of this title.”
35 U.S.C. § 101
Eligibility: Judicial Exceptions
• Laws of nature
• Natural phenomena
• Abstract ideas
Eligibility: Judicial Exceptions
• scientific principles
• naturally occurring phenomena
• mental processes
• mathematical algorithms
Practical application of
natural phenomenon
Life Science Challenge:
The Reality of
Past 5 Years
1631 Art Unit
Molecular Bio,
Bioinformatics, Nucleic
Acids, Recombinant
DNA/RNA, Gene
Regulation
Mayo Collaborative Services v.
Prometheus Laboratories, Inc.
Unpatentable natural laws transformed into patent-eligible
applications of those laws?
Statutory
Category?
YES Judicial
Exception?
Practical
Application?
YES Significantly
More?
NO
YES
NO
YES
Eligible
NO
Subject Matter Eligibility Guidance
Process
machine
manufacture
composition of matter
Laws of nature
Natural phenomena
Abstract ideas
Not Eligible
NO
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
A significant, but unpatentable, contribution to the medical field.
The solution lies in the intent
“…in applying the §101 exception, we must distinguish
between patents that claim the building blocks of
human ingenuity and those that integrate the
building blocks into something more, thereby
transforming them into a patent-eligible invention”
Alice Corp. v. CLS Bank Int’l SCOTUS opinion
The solution lies in the intent
“At some level, all inventions embody, use, reflect, rest upon,
or apply laws of nature, natural phenomena, or abstract
ideas. Thus, an invention is not rendered ineligible for patent
simply because it involves an abstract concept. Applications
of such concepts to a new and useful end … remain eligible
for patent protection.”
Alice Corp. v. CLS Bank Int’l SCOTUS opinion
Key Tips for Derisking Eligibility
• Practical applications.
• Improvement over prior art methods.
• Overcome a particular technical challenge.
• Different claim types.
Building blocks into something more
"Unless you puke, faint or die, keep going!"
– Jillian Michaels
Enablement.
The fundamental deal of the patent system.
Enablement: Adequate Description
“The specification shall contain a written description of
the invention, and of the manner and process of
making and using it, in such full, clear, concise, and
exact terms as to enable any person skilled in the art
… to make and use the same…”
35 U.S.C. § 112
Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
101
Patentable
Subject Matter
102
Novelty
103
Obviousness
112a
Written
Description
112b
Enablement
All
Rejection
Bases
Top Art Unit
Groups
for 112
Rejections
Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
Higher disclosure bar for
unpredictable arts
Life Science Challenge:
Enabling Unpredictable Arts
“the scope of enablement … varies inversely with
the degree of unpredictability of the factors involved”
Application of Joseph D. Fisher, 427 F.2d 833 (C.C.P.A. 1970)
Enablement
Mechanical arts
Physics
Chemical arts
Life Sciences
Predictability
Digital Health
The Enablement Test
“…as to enable any person skilled in the art … to make
and use the … invention.”
35 U.S.C. § 112
“…without undue experimentation”.
Minerals Separation Ltd. v. Hyde
... coupled with information known in the art ...”.
United States v. Telectronics, Inc
Genus Claim: covers a group of related
chemicals
Species Claim: covers a single compound or
narrow slice of compounds possibly without
coverage of analogs, derivatives, or
compounds in the same family
…the law has changed dramatically in the last thirty
years, to the point where it is nearly impossible to
maintain a valid genus claim. Courts almost always
hold them invalid, either at trial or on appeal.
“
Harvard Journal of Law & Technology: Death of the Genus Claim
USPTO Genus Misinformation
Disputed by Third Parties
Community reports have identified this guidance as violating the
Community Policy on Harmfully Misleading Information
United States Patent and Trademark Office
MPEP
III. WORKING EXAMPLES AND A CLAIMED GENUS
For a claimed genus, representative examples together with a statement applicable to
the genus as a whole will ordinarily be sufficient if one skilled in the art …would expect
the claimed genus could be used in that manner without undue experimentation.
Proof of enablement will be required for other members of the claimed genus only
where adequate reasons are advanced by the examiner to establish that a person
skilled in the art could not use the genus as a whole without undue experimentation.
Examples of the Genus Claim Deaths
• A nascent, unpredictable field rife with failure
can cause enablement issues
–Enzo Biochem v. Calgene (Fed. Circ. 1999)
–Claimed antisense DNA technology
• Iterative trial-and-error lead by spec can
create enablement issue
–Wyeth v. Abbott (Fed. Circ. 2010)
–Rapamycin chemicals for treatment of
restenosis
Death of the Genus Claim
• Undue Experimentation despite described
screening process allowing for straightforward ID
of working embodiments
– Idenix Pharma v. Gilead (Fed. Circ. 2019)
– 2-methyl nucleoside for treatment of HCV
• Not Enabled despite antibody science being well-
known, guidance provided, working examples,
identified specific amino acids for binding
– Amgen v. Sanofi (Supreme Court 2023)
The solution lies in the intent
A bargain between the inventor and society.
Wands Factors
1. Quantity of experimentation necessary
2. Amount of direction or guidance presented
3. Presence or absence of working examples
4. Nature of the invention
5. State of the prior art
6. Relative skill of those in the art
7. Predictability or unpredictability of the art
8. Breadth of the claims
In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
Key Tips for Derisking Enablement
• Provide ample direction and specificity.
• Build breadth through examples.
• Reinforce genus with species.
• Consider a narrower claim backstop.
• Disclose experimentation tips.
• File continuation applications.
• Consider alternative strategies.
Funding Sources and
Regulatory Delays
Life Science Challenges:
Gov’t grants
come with
strings
attached…
SBIR / STTR
Government Grant Gotchyas
1. Actually reduce invention to practice before using money –
otherwise Gov’t has a nonexclusive, nontransferrable,
irrevocable, paid-up license to practice the invention
throughout the world
• Even if your patent was filed before the grant….
2. If subject invention is unelected at 2 years, then gov’t
receives title of invention.
3. If hire subcontractor to perform some of the work, any subject
invention from the subcontractor cannot be assigned to your
company – subcontractor retains ownership.
Stronger Life Science Patents (MichBio)
Maximize Your Exclusivity Window
1. Patent Term Extension
2. New Drug Product Exclusivity
3. New Clinical Investigation Exclusivity
“trainers who say ‘last one’ are the
reason I have trust issues"
Reform on the horizon?
Current events and legislative solutions.
Patent Eligibility Restoration Act of 2023
• Would amend the U.S. Patent Act to clarify the
application of 35 U.S.C. Section 101 and address
uncertainty plaguing software and biotechnology
inventions
• Effectively overruling Alice and previous SCOTUS cases
such as Mayo
• Wide bipartisan and community support
Stronger Life Science Patents (MichBio)
Stronger Life
Science Patent
Resources
• This slide deck
• Blog posts on timelines and exclusivity
• Podcasts on enablement and gov’t grants
Questions or Comments?
Contact us!
ashley@aurorapatents.com
(231) 715-1001
aurorapatents.com
@AuroraPatents
Podcast @ patentlystrategic.buzzsprout.com
1 de 52

Recomendados

2017 01-25 uwls-apl_biotech 112 por
2017 01-25 uwls-apl_biotech 1122017 01-25 uwls-apl_biotech 112
2017 01-25 uwls-apl_biotech 112Gary M. Myles, Ph.D.
239 visualizações59 slides
The Case Of Incyte Genomics por
The Case Of Incyte GenomicsThe Case Of Incyte Genomics
The Case Of Incyte Genomicsjrstorella
1.2K visualizações21 slides
Enforcement and Patentable Subject Matter: The U.S. Dilemma por
Enforcement and Patentable Subject Matter: The U.S. DilemmaEnforcement and Patentable Subject Matter: The U.S. Dilemma
Enforcement and Patentable Subject Matter: The U.S. DilemmaPatterson Thuente IP
50 visualizações31 slides
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne... por
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...
Ethical Issues Surrounding Patenting of Human Genes and the Development of Ne...Stephen Cranwell
444 visualizações6 slides
Biotechnology Novelty And Nonobviousness 14 Sep10 por
Biotechnology Novelty And Nonobviousness 14 Sep10Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10Gary M. Myles, Ph.D.
275 visualizações52 slides
Gene Patenting Life By Michael Crichton Summary por
Gene Patenting Life By Michael Crichton SummaryGene Patenting Life By Michael Crichton Summary
Gene Patenting Life By Michael Crichton SummarySue Jones
2 visualizações42 slides

Mais conteúdo relacionado

Similar a Stronger Life Science Patents (MichBio)

THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES por
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESTHE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESSaravanan A
807 visualizações27 slides
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 por
2020 01-28 uwls-apl_biotech_disclosure under 35_usc1122020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112Gary M. Myles, Ph.D.
61 visualizações45 slides
11 Biotechnology Patents_Subject Matter Exclusions.pptx por
11 Biotechnology Patents_Subject Matter Exclusions.pptx11 Biotechnology Patents_Subject Matter Exclusions.pptx
11 Biotechnology Patents_Subject Matter Exclusions.pptxssuserdf29f0
29 visualizações28 slides
Patent Year In Review 2011 60 Minutes Slides por
Patent Year In Review 2011 60 Minutes SlidesPatent Year In Review 2011 60 Minutes Slides
Patent Year In Review 2011 60 Minutes Slidesemanzo7672
468 visualizações79 slides
Biotechnology Patent Eligibility por
Biotechnology Patent EligibilityBiotechnology Patent Eligibility
Biotechnology Patent EligibilityGary M. Myles, Ph.D.
895 visualizações97 slides
Gene patenting por
Gene patentingGene patenting
Gene patentingHina Zamir Noori
5.4K visualizações5 slides

Similar a Stronger Life Science Patents (MichBio)(20)

THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES por Saravanan A
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESTHE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENES
Saravanan A807 visualizações
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 por Gary M. Myles, Ph.D.
2020 01-28 uwls-apl_biotech_disclosure under 35_usc1122020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
Gary M. Myles, Ph.D.61 visualizações
11 Biotechnology Patents_Subject Matter Exclusions.pptx por ssuserdf29f0
11 Biotechnology Patents_Subject Matter Exclusions.pptx11 Biotechnology Patents_Subject Matter Exclusions.pptx
11 Biotechnology Patents_Subject Matter Exclusions.pptx
ssuserdf29f029 visualizações
Patent Year In Review 2011 60 Minutes Slides por emanzo7672
Patent Year In Review 2011 60 Minutes SlidesPatent Year In Review 2011 60 Minutes Slides
Patent Year In Review 2011 60 Minutes Slides
emanzo7672468 visualizações
Biotechnology Patent Eligibility por Gary M. Myles, Ph.D.
Biotechnology Patent EligibilityBiotechnology Patent Eligibility
Biotechnology Patent Eligibility
Gary M. Myles, Ph.D.895 visualizações
Gene patenting por Hina Zamir Noori
Gene patentingGene patenting
Gene patenting
Hina Zamir Noori5.4K visualizações
Patentability of Diagnostic Inventions por Marcus A. Streips
Patentability of Diagnostic InventionsPatentability of Diagnostic Inventions
Patentability of Diagnostic Inventions
Marcus A. Streips616 visualizações
Predictable Results from Unpredictable Arts por Aurora Consulting
Predictable Results from Unpredictable ArtsPredictable Results from Unpredictable Arts
Predictable Results from Unpredictable Arts
Aurora Consulting467 visualizações
Patents and intellectual property por Janet Stemwedel
Patents and intellectual propertyPatents and intellectual property
Patents and intellectual property
Janet Stemwedel657 visualizações
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005 por SterneKessler
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SterneKessler320 visualizações
Biotech Patentable Subject Matter After Bilski por wardjohn1346
Biotech Patentable Subject Matter After BilskiBiotech Patentable Subject Matter After Bilski
Biotech Patentable Subject Matter After Bilski
wardjohn1346597 visualizações
Non patentable inventions in india por atuljaybhaye
Non patentable inventions in indiaNon patentable inventions in india
Non patentable inventions in india
atuljaybhaye1.3K visualizações
NPE Patent Litigation Latest Developments por Parsons Behle & Latimer
NPE Patent Litigation Latest DevelopmentsNPE Patent Litigation Latest Developments
NPE Patent Litigation Latest Developments
Parsons Behle & Latimer1.3K visualizações
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et... por Lawrence Kass
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...
2002 AIPLA - Kass & Nitabach, A Roadmap For Biotechnology Patents, by Kass et...
Lawrence Kass186 visualizações
2017 02-15 uwls-apl_biotech 101 por Gary M. Myles, Ph.D.
2017 02-15 uwls-apl_biotech 1012017 02-15 uwls-apl_biotech 101
2017 02-15 uwls-apl_biotech 101
Gary M. Myles, Ph.D.202 visualizações
Feb Biocom panel por Erica Pascal
Feb Biocom panelFeb Biocom panel
Feb Biocom panel
Erica Pascal240 visualizações
016 patent infringement por 456 986
016 patent infringement016 patent infringement
016 patent infringement
456 9862.3K visualizações
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth... por Kirby Drake
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Kirby Drake50 visualizações
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t... por Patterson Thuente IP
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...
Issues in U.S. Biotech and Pharma Patenting: Patentable Subject Matter: and t...
Patterson Thuente IP81 visualizações
The Patent Law Of Taiwan por Susan Migliaccio
The Patent Law Of TaiwanThe Patent Law Of Taiwan
The Patent Law Of Taiwan
Susan Migliaccio2 visualizações

Mais de Aurora Consulting

Patent Claims por
Patent ClaimsPatent Claims
Patent ClaimsAurora Consulting
173 visualizações23 slides
Protect Before You Pitch (MichBio) por
Protect Before You Pitch (MichBio)Protect Before You Pitch (MichBio)
Protect Before You Pitch (MichBio)Aurora Consulting
42 visualizações10 slides
Government Grants and Patent Rights por
Government Grants and Patent RightsGovernment Grants and Patent Rights
Government Grants and Patent RightsAurora Consulting
237 visualizações18 slides
Open Source and Patent Rights: Collaboration with Consequences por
Open Source and Patent Rights: Collaboration with ConsequencesOpen Source and Patent Rights: Collaboration with Consequences
Open Source and Patent Rights: Collaboration with ConsequencesAurora Consulting
392 visualizações18 slides
Amgen V. Sanofi.pdf por
Amgen V. Sanofi.pdfAmgen V. Sanofi.pdf
Amgen V. Sanofi.pdfAurora Consulting
631 visualizações29 slides
Foreign Filing Licenses por
Foreign Filing LicensesForeign Filing Licenses
Foreign Filing LicensesAurora Consulting
469 visualizações16 slides

Mais de Aurora Consulting(20)

Patent Claims por Aurora Consulting
Patent ClaimsPatent Claims
Patent Claims
Aurora Consulting173 visualizações
Protect Before You Pitch (MichBio) por Aurora Consulting
Protect Before You Pitch (MichBio)Protect Before You Pitch (MichBio)
Protect Before You Pitch (MichBio)
Aurora Consulting42 visualizações
Government Grants and Patent Rights por Aurora Consulting
Government Grants and Patent RightsGovernment Grants and Patent Rights
Government Grants and Patent Rights
Aurora Consulting237 visualizações
Open Source and Patent Rights: Collaboration with Consequences por Aurora Consulting
Open Source and Patent Rights: Collaboration with ConsequencesOpen Source and Patent Rights: Collaboration with Consequences
Open Source and Patent Rights: Collaboration with Consequences
Aurora Consulting392 visualizações
Amgen V. Sanofi.pdf por Aurora Consulting
Amgen V. Sanofi.pdfAmgen V. Sanofi.pdf
Amgen V. Sanofi.pdf
Aurora Consulting631 visualizações
Foreign Filing Licenses por Aurora Consulting
Foreign Filing LicensesForeign Filing Licenses
Foreign Filing Licenses
Aurora Consulting469 visualizações
Top 3 Inventor Mistakes por Aurora Consulting
Top 3 Inventor MistakesTop 3 Inventor Mistakes
Top 3 Inventor Mistakes
Aurora Consulting473 visualizações
Into the Patentverse Vol. 2: AR, VR, and Virtual Infringement por Aurora Consulting
Into the Patentverse Vol. 2: AR, VR, and Virtual InfringementInto the Patentverse Vol. 2: AR, VR, and Virtual Infringement
Into the Patentverse Vol. 2: AR, VR, and Virtual Infringement
Aurora Consulting468 visualizações
Mean Plus Function: : The Risk of Losing Your Way por Aurora Consulting
Mean Plus Function: : The Risk of Losing Your WayMean Plus Function: : The Risk of Losing Your Way
Mean Plus Function: : The Risk of Losing Your Way
Aurora Consulting538 visualizações
American Axle: 101 Rejections of Mechanical Claims por Aurora Consulting
American Axle: 101 Rejections of Mechanical ClaimsAmerican Axle: 101 Rejections of Mechanical Claims
American Axle: 101 Rejections of Mechanical Claims
Aurora Consulting529 visualizações
Prenuptial Patenting: Responsible Engagement with Engineering Firms por Aurora Consulting
Prenuptial Patenting: Responsible Engagement with Engineering FirmsPrenuptial Patenting: Responsible Engagement with Engineering Firms
Prenuptial Patenting: Responsible Engagement with Engineering Firms
Aurora Consulting434 visualizações
Fortifying Life Science Patents: Eligibility and Enablement por Aurora Consulting
Fortifying Life Science Patents: Eligibility and EnablementFortifying Life Science Patents: Eligibility and Enablement
Fortifying Life Science Patents: Eligibility and Enablement
Aurora Consulting440 visualizações
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTs por Aurora Consulting
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTsWeb 3 and IP: Cryptocurrencies, Blockchain, and NFTs
Web 3 and IP: Cryptocurrencies, Blockchain, and NFTs
Aurora Consulting507 visualizações
Common Ownership por Aurora Consulting
Common OwnershipCommon Ownership
Common Ownership
Aurora Consulting405 visualizações
Inventorship: Who should be listed as an inventor for a patent? por Aurora Consulting
Inventorship: Who should be listed as an inventor for a patent?Inventorship: Who should be listed as an inventor for a patent?
Inventorship: Who should be listed as an inventor for a patent?
Aurora Consulting553 visualizações
Decrypting Software Patents: Key Insights for IP Success por Aurora Consulting
Decrypting Software Patents: Key Insights for IP SuccessDecrypting Software Patents: Key Insights for IP Success
Decrypting Software Patents: Key Insights for IP Success
Aurora Consulting677 visualizações
Patent Searching: Sleuthing Your Way to Stronger Patents por Aurora Consulting
Patent Searching: Sleuthing Your Way to Stronger PatentsPatent Searching: Sleuthing Your Way to Stronger Patents
Patent Searching: Sleuthing Your Way to Stronger Patents
Aurora Consulting663 visualizações
Global & U.S. Patents for Digital Health Startups por Aurora Consulting
Global & U.S. Patents for Digital Health StartupsGlobal & U.S. Patents for Digital Health Startups
Global & U.S. Patents for Digital Health Startups
Aurora Consulting55 visualizações
Google v Oracle: The Future of Software and Fair Use por Aurora Consulting
Google v Oracle: The Future of Software and Fair UseGoogle v Oracle: The Future of Software and Fair Use
Google v Oracle: The Future of Software and Fair Use
Aurora Consulting728 visualizações
A Pathway for Pharmaceutical Patents por Aurora Consulting
A Pathway for Pharmaceutical PatentsA Pathway for Pharmaceutical Patents
A Pathway for Pharmaceutical Patents
Aurora Consulting68 visualizações

Último

Western Blotting (Protein Separation technique) .pptx por
Western Blotting (Protein Separation technique) .pptxWestern Blotting (Protein Separation technique) .pptx
Western Blotting (Protein Separation technique) .pptxAnkit Mehra
55 visualizações9 slides
Gastro-retentive drug delivery systems.pptx por
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptxABG
242 visualizações32 slides
Correct handling of laboratory Rats ppt.pptx por
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptxTusharChaudhary99
34 visualizações12 slides
Impact of ICF on collaboration and communication por
Impact of ICF on collaboration and communicationImpact of ICF on collaboration and communication
Impact of ICF on collaboration and communicationOlaf Kraus de Camargo
29 visualizações19 slides
Vyadhikshmatva.pptx 1.pptx por
Vyadhikshmatva.pptx 1.pptxVyadhikshmatva.pptx 1.pptx
Vyadhikshmatva.pptx 1.pptxAkshay Shetty
58 visualizações29 slides
Community Medicine by Ikpanor Benjamin.pptx por
Community Medicine by Ikpanor Benjamin.pptxCommunity Medicine by Ikpanor Benjamin.pptx
Community Medicine by Ikpanor Benjamin.pptxCollege of Health Sciences, Benue State University Makurdi
54 visualizações56 slides

Último(20)

Western Blotting (Protein Separation technique) .pptx por Ankit Mehra
Western Blotting (Protein Separation technique) .pptxWestern Blotting (Protein Separation technique) .pptx
Western Blotting (Protein Separation technique) .pptx
Ankit Mehra55 visualizações
Gastro-retentive drug delivery systems.pptx por ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG242 visualizações
Correct handling of laboratory Rats ppt.pptx por TusharChaudhary99
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptx
TusharChaudhary9934 visualizações
Impact of ICF on collaboration and communication por Olaf Kraus de Camargo
Impact of ICF on collaboration and communicationImpact of ICF on collaboration and communication
Impact of ICF on collaboration and communication
Olaf Kraus de Camargo29 visualizações
Vyadhikshmatva.pptx 1.pptx por Akshay Shetty
Vyadhikshmatva.pptx 1.pptxVyadhikshmatva.pptx 1.pptx
Vyadhikshmatva.pptx 1.pptx
Akshay Shetty58 visualizações
CHOLESTEROL SYNTHESIS.pptx por SiphyThindwa1
CHOLESTEROL SYNTHESIS.pptxCHOLESTEROL SYNTHESIS.pptx
CHOLESTEROL SYNTHESIS.pptx
SiphyThindwa114 visualizações
Size reduction.pptx por shubhammhaske31
Size reduction.pptxSize reduction.pptx
Size reduction.pptx
shubhammhaske3120 visualizações
vitamin E.pptx por ajithkilpart
vitamin E.pptxvitamin E.pptx
vitamin E.pptx
ajithkilpart18 visualizações
Scrotal and Testicular Swelling.pptx por Michael Sintayehu
Scrotal and Testicular Swelling.pptxScrotal and Testicular Swelling.pptx
Scrotal and Testicular Swelling.pptx
Michael Sintayehu23 visualizações
functional gait assessment.pdf por mhmad farooq
functional gait assessment.pdffunctional gait assessment.pdf
functional gait assessment.pdf
mhmad farooq10 visualizações
Quit Smoking Revolution.pdf por Gio Ferrandino
Quit Smoking Revolution.pdfQuit Smoking Revolution.pdf
Quit Smoking Revolution.pdf
Gio Ferrandino29 visualizações
CCDI Kibbe Wake Forest University Dec 2023.pptx por Warren Kibbe
CCDI Kibbe Wake Forest University Dec 2023.pptxCCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptx
Warren Kibbe20 visualizações
MAINTAINING A HEALTHY LIFE.doc por Dr. MWEBAZA VICTOR
MAINTAINING A HEALTHY LIFE.docMAINTAINING A HEALTHY LIFE.doc
MAINTAINING A HEALTHY LIFE.doc
Dr. MWEBAZA VICTOR 65 visualizações
BIPHASIC LIQUID DOSAGE FORMS priyanka kandhare por Priyanka Kandhare
BIPHASIC LIQUID DOSAGE FORMS priyanka kandhareBIPHASIC LIQUID DOSAGE FORMS priyanka kandhare
BIPHASIC LIQUID DOSAGE FORMS priyanka kandhare
Priyanka Kandhare19 visualizações
Ros Wilson - Future of Ageing 2023 por ILCUK
Ros Wilson - Future of Ageing 2023Ros Wilson - Future of Ageing 2023
Ros Wilson - Future of Ageing 2023
ILCUK32 visualizações

Stronger Life Science Patents (MichBio)

  • 1. Stronger Life Science Patents This presentation is for information purposes only and does not constitute legal advice. ASHLEY SLOAT, Ph.D. | September 18, 2023
  • 2. Ashley Sloat, Ph.D. President & Director of Patent Strategy
  • 3. an illogical, unpredictable, chaotic mess... “ – Federal Circuit Chief Judge Paul Michel (retired)
  • 4. made it difficult for inventors, businesses, and other patent stakeholders to reliably and predictably determine what subject matter is patent eligible “ – Elizabeth Prelogar, U.S. Solicitor General
  • 5. innovation cannot thrive in uncertainty “ – Kathi Vidal, USPTO Director and Under Secretary of Commerce
  • 6. 80% innovation does not include patentable subject matter
  • 8. Let us be clear: investments in the biotech industry are based entirely on patents. Without strong patents, we cannot raise money to find cures for disease. “ – Hans Bishop, Founder at Altos Labs & former Head of Juno Therapeutics
  • 10. Overview: Stronger Life Science Patents •Eligibility and enablement •State of the law •Funding sources and regulatory delays •Practical tips •Recent legislative movements
  • 11. There are seven days in the week and SOMEDAY isn’t one of them. “
  • 12. Rejection & Invalidation Gates • Section 101 – patent ineligibility or lack of utility • Section 102 – lack of novelty • Section 103 – the claimed invention is obvious and/or • Section 112 – lack of adequate description
  • 13. Eligibility. What subject matters are eligible for patent protection?
  • 14. Enablement. The fundamental deal of the patent system.
  • 15. Eligibility: Patentable Subject Matter “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” 35 U.S.C. § 101
  • 16. Eligibility: Judicial Exceptions • Laws of nature • Natural phenomena • Abstract ideas
  • 17. Eligibility: Judicial Exceptions • scientific principles • naturally occurring phenomena • mental processes • mathematical algorithms
  • 18. Practical application of natural phenomenon Life Science Challenge:
  • 19. The Reality of Past 5 Years 1631 Art Unit Molecular Bio, Bioinformatics, Nucleic Acids, Recombinant DNA/RNA, Gene Regulation
  • 20. Mayo Collaborative Services v. Prometheus Laboratories, Inc. Unpatentable natural laws transformed into patent-eligible applications of those laws?
  • 21. Statutory Category? YES Judicial Exception? Practical Application? YES Significantly More? NO YES NO YES Eligible NO Subject Matter Eligibility Guidance Process machine manufacture composition of matter Laws of nature Natural phenomena Abstract ideas Not Eligible NO
  • 22. Ariosa Diagnostics, Inc. v. Sequenom, Inc. A significant, but unpatentable, contribution to the medical field.
  • 23. The solution lies in the intent “…in applying the §101 exception, we must distinguish between patents that claim the building blocks of human ingenuity and those that integrate the building blocks into something more, thereby transforming them into a patent-eligible invention” Alice Corp. v. CLS Bank Int’l SCOTUS opinion
  • 24. The solution lies in the intent “At some level, all inventions embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas. Thus, an invention is not rendered ineligible for patent simply because it involves an abstract concept. Applications of such concepts to a new and useful end … remain eligible for patent protection.” Alice Corp. v. CLS Bank Int’l SCOTUS opinion
  • 25. Key Tips for Derisking Eligibility • Practical applications. • Improvement over prior art methods. • Overcome a particular technical challenge. • Different claim types. Building blocks into something more
  • 26. "Unless you puke, faint or die, keep going!" – Jillian Michaels
  • 27. Enablement. The fundamental deal of the patent system.
  • 28. Enablement: Adequate Description “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art … to make and use the same…” 35 U.S.C. § 112
  • 29. Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them 101 Patentable Subject Matter 102 Novelty 103 Obviousness 112a Written Description 112b Enablement All Rejection Bases
  • 30. Top Art Unit Groups for 112 Rejections Source: IPW 112 Rejections: Where They Are Found and How Applicants Handle Them
  • 31. Higher disclosure bar for unpredictable arts Life Science Challenge:
  • 32. Enabling Unpredictable Arts “the scope of enablement … varies inversely with the degree of unpredictability of the factors involved” Application of Joseph D. Fisher, 427 F.2d 833 (C.C.P.A. 1970) Enablement Mechanical arts Physics Chemical arts Life Sciences Predictability Digital Health
  • 33. The Enablement Test “…as to enable any person skilled in the art … to make and use the … invention.” 35 U.S.C. § 112 “…without undue experimentation”. Minerals Separation Ltd. v. Hyde ... coupled with information known in the art ...”. United States v. Telectronics, Inc
  • 34. Genus Claim: covers a group of related chemicals Species Claim: covers a single compound or narrow slice of compounds possibly without coverage of analogs, derivatives, or compounds in the same family
  • 35. …the law has changed dramatically in the last thirty years, to the point where it is nearly impossible to maintain a valid genus claim. Courts almost always hold them invalid, either at trial or on appeal. “ Harvard Journal of Law & Technology: Death of the Genus Claim
  • 36. USPTO Genus Misinformation Disputed by Third Parties Community reports have identified this guidance as violating the Community Policy on Harmfully Misleading Information United States Patent and Trademark Office MPEP III. WORKING EXAMPLES AND A CLAIMED GENUS For a claimed genus, representative examples together with a statement applicable to the genus as a whole will ordinarily be sufficient if one skilled in the art …would expect the claimed genus could be used in that manner without undue experimentation. Proof of enablement will be required for other members of the claimed genus only where adequate reasons are advanced by the examiner to establish that a person skilled in the art could not use the genus as a whole without undue experimentation.
  • 37. Examples of the Genus Claim Deaths • A nascent, unpredictable field rife with failure can cause enablement issues –Enzo Biochem v. Calgene (Fed. Circ. 1999) –Claimed antisense DNA technology • Iterative trial-and-error lead by spec can create enablement issue –Wyeth v. Abbott (Fed. Circ. 2010) –Rapamycin chemicals for treatment of restenosis
  • 38. Death of the Genus Claim • Undue Experimentation despite described screening process allowing for straightforward ID of working embodiments – Idenix Pharma v. Gilead (Fed. Circ. 2019) – 2-methyl nucleoside for treatment of HCV • Not Enabled despite antibody science being well- known, guidance provided, working examples, identified specific amino acids for binding – Amgen v. Sanofi (Supreme Court 2023)
  • 39. The solution lies in the intent A bargain between the inventor and society.
  • 40. Wands Factors 1. Quantity of experimentation necessary 2. Amount of direction or guidance presented 3. Presence or absence of working examples 4. Nature of the invention 5. State of the prior art 6. Relative skill of those in the art 7. Predictability or unpredictability of the art 8. Breadth of the claims In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
  • 41. Key Tips for Derisking Enablement • Provide ample direction and specificity. • Build breadth through examples. • Reinforce genus with species. • Consider a narrower claim backstop. • Disclose experimentation tips. • File continuation applications. • Consider alternative strategies.
  • 42. Funding Sources and Regulatory Delays Life Science Challenges:
  • 44. Government Grant Gotchyas 1. Actually reduce invention to practice before using money – otherwise Gov’t has a nonexclusive, nontransferrable, irrevocable, paid-up license to practice the invention throughout the world • Even if your patent was filed before the grant…. 2. If subject invention is unelected at 2 years, then gov’t receives title of invention. 3. If hire subcontractor to perform some of the work, any subject invention from the subcontractor cannot be assigned to your company – subcontractor retains ownership.
  • 46. Maximize Your Exclusivity Window 1. Patent Term Extension 2. New Drug Product Exclusivity 3. New Clinical Investigation Exclusivity
  • 47. “trainers who say ‘last one’ are the reason I have trust issues"
  • 48. Reform on the horizon? Current events and legislative solutions.
  • 49. Patent Eligibility Restoration Act of 2023 • Would amend the U.S. Patent Act to clarify the application of 35 U.S.C. Section 101 and address uncertainty plaguing software and biotechnology inventions • Effectively overruling Alice and previous SCOTUS cases such as Mayo • Wide bipartisan and community support
  • 51. Stronger Life Science Patent Resources • This slide deck • Blog posts on timelines and exclusivity • Podcasts on enablement and gov’t grants
  • 52. Questions or Comments? Contact us! ashley@aurorapatents.com (231) 715-1001 aurorapatents.com @AuroraPatents Podcast @ patentlystrategic.buzzsprout.com